Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The archive
Page 20 of 170 of this archive, newest first.
The degradation product that elutes underneath the parent peak
Deamidation, oxidation, aggregation and hydrolysis account for nearly all of what happens to a peptide over time. Each has a characteristic residue, a characteristic…
Target dose, effective dose, and the distance between them
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Inspectors cite Halvard & Pike Apothecary of Portland, Maine over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Independent analysis puts a BCH mazdutide lot at 96.0%, against 93.7% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
REWIND was built to answer the stopping question, and it did
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Which results are findings and which are consequences of the weight loss
A substantial proportion of the abnormal results generated during rapid weight loss are consequences of the weight loss rather than findings about the person.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 15% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
What actually helps, ranked by evidence
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
An interlaboratory comparison nobody had run
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Independent analysis puts a MKM liraglutide lot at 99.0%, against 97.4% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The United Kingdom declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 7 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The imaging substudy is an afterthought in the protocol and the centrepiece of the debate
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
Aseptic technique for people who were never taught it
For licensed products the in-use period is established by stability data. For a peptide reconstituted at home there is no such data, and the honest answer is that nobody…
One receptor, several signals: the case for reading liraglutide as a biased agonist
Receptor pharmacology explains more of the clinical picture than the dose does — and almost none of it appears in the material patients are given.
PeptideMeter result on a Guangzhou exenatide lot lands 4.3 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
From the floor in Hangzhou: 23 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
SELECT misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
An interlaboratory comparison nobody had run
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A shortage listing ends. 10 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
STEP 5 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The generic peptide method, and what it was designed for
A shallow gradient resolves impurities that a steep one runs into the parent peak. Both methods are legitimate; only one of them can see the small stuff.